CREATE Medicines: Funding, Investors & Team (Sep 2026)

CREATE Medicines is a clinical-stage biotechnology company focused on developing RNA-based immunotherapies through in vivo immune cell programming. Its platform uses proprietary mRNA-lipid nanoparticle (mRNA-LNP) technology to directly program immune cells such as T cells, NK cells, and myeloid cells within the body, with applications in cancer, autoimmune diseases, and fibrosis. The company is advancing a pipeline of in vivo CAR therapies, including programs for breast cancer, epithelial tumors, and B cell depletion, with several candidates currently in clinical and preclinical development. CREATE Medicines also develops targeted receptor and RNA engineering technologies designed to support repeat dosing and multi-immune cell programming. Its research and clinical efforts are centered on creating scalable immunotherapy approaches that avoid the need for traditional ex vivo cell engineering processes.

CREATE Medicines has raised $122M across 1 round on record. The most recent is a Series B of $122M announced in May 2026.

CREATE Medicines' most recent funding round on record is a Series B of $122M, announced in May 2026.

FundedIQ lists Daniel G (Founder) at CREATE Medicines.

CREATE Medicines is based in Cambridge, Massachusetts, United States.

CREATE Medicines is in the 11-50 employee band.

CREATE Medicines' latest round of $122M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.